LEXICON PHARMACEUTICALS, INC. (LXRX) Total liabilities 2016–2025
LEXICON PHARMACEUTICALS, INC. (LXRX) total liabilities at each fiscal year-end, per SEC filings.
$77.4MFY2025 · since FY2016: $318.2M → $77.4M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $77.4M | -49.2% |
| FY2024 | $152.5M | +11.8% |
| FY2023 | $136.3M | +76.6% |
| FY2022 | $77.2M | +231.0% |
| FY2021 | $23.3M | -50.8% |
| FY2020 | $47.4M | -84.2% |
| FY2019 | $300.6M | -3.2% |
| FY2018 | $310.5M | -15.7% |
| FY2017 | $368.3M | +15.7% |
| FY2016 | $318.2M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More LXRX financial trends
LXRX RevenueLXRX Net incomeLXRX Net marginLXRX Gross profitLXRX Gross marginLXRX Operating incomeLXRX Operating marginLXRX Operating cash flowLXRX Free cash flowLXRX Capital expendituresLXRX Return on equityLXRX Stock buybacksLXRX Dividends paidLXRX Total assetsLXRX Shareholders’ equityLXRX overview →